Acylcarnitine Metabolomic Profiles Inform Clinically-Defined Major Depressive Phenotypes
Ahmed T. Ahmed,
M. Arthur Moseley,
J. Will Thompson,
Lisa St. John Williams,
Michelle K. Skime,
William V. Bobo,
W. Edward Craighead,
Richard M. Weinshilboum,
Boadie W. Dunlop,
David S. Millington,
A. John Rush,
Mark A Frye,
The Mood Disorders Precision Medicine Consortium (MDPMC),
Posted 09 May 2019
bioRxiv DOI: 10.1101/632448 (published DOI: 10.1016/j.jad.2019.11.122)
Posted 09 May 2019
Background: Acylcarnitines have important functions in mitochondrial energetics and β-oxidation, and have been implicated to play a significant role in metabolic functions of the brain. This retrospective study examined whether plasma acylcarnitine profiles can help biochemically distinguish the three phenotypic subtypes of major depressive disorder (MDD) ,(core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+)),following treatment with a selective serotonin reuptake inhibitor (SSRI). Methods: Depressed outpatients (n=240) from the Mayo Clinic Pharmacogenomics Research Network were treated with citalopram or escitalopram for eight weeks. Plasma samples collected at baseline and eight weeks post-treatment were profiled for multiple-, short-, medium- and long-chain acylcarnitine levels using AbsoluteIDQ p180-Kit and LC-MS. Linear mixed effects models were used to examine whether acylcarnitine levels discriminate the clinical phenotypes at baseline or eight weeks post-treatment, and whether temporal changes in acylcarnitine profiles differ between groups. Results: At baseline, significantly lower concentrations of short- and long-chain acylcarnitines were found in CD+ and NVSM+ compared to ANX+, and the short-chain acylcarnitines remained lower after eight weeks. At eight weeks, the medium- and long-chain acylcarnitines were significantly lower in NVSM+ compared to ANX+. Regarding changes baseline to week eight, short-chain acylcarnitine levels significantly increased in CD+ and ANX+, and medium- and long-chain acylcarnitines significantly decreased in NVSM+ and CD+. Conclusions: In depressed patients treated with SSRIs, β-oxidation and mitochondrial energetics as evaluated by levels and changes in acylcarnitines may provide the biochemical basis of the clinical heterogeneity of MDD, especially when combined with clinical characteristics.
- Downloaded 406 times
- Download rankings, all-time:
- Site-wide: 42,544 out of 94,912
- In biochemistry: 1,258 out of 3,211
- Year to date:
- Site-wide: 63,309 out of 94,912
- Since beginning of last month:
- Site-wide: 58,778 out of 94,912
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!